Tokyo Tape
Sign in
← Trans Genic

Quarterly report · Q3

2342.TEDINET S100Q04J
Period2022-04-01 → 2022-12-31
Filed2023-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 35
MetricValuePeriodScopeSource row
Revenue¥8.5bn2022-04-01 → 2022-12-31Cons.Net sales
Revenue¥12.6bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥9.6bn2021-04-01 → 2021-12-31Cons.Net sales
Operating income¥153m2022-04-01 → 2022-12-31Cons.Operating income
Operating income¥1.7bn2021-04-01 → 2021-12-31Cons.Operating income
Ordinary income¥385m2022-04-01 → 2022-12-31Cons.Ordinary income
Ordinary income¥1.8bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥1.7bn2021-04-01 → 2021-12-31Cons.Ordinary income
Profit before tax¥344m2022-04-01 → 2022-12-31Cons.Income before income taxes
Profit before tax¥1.4bn2021-04-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)¥182m2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥1.9bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥803m2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income¥171m2022-04-01 → 2022-12-31Cons.Profit loss
Net income¥795m2021-04-01 → 2021-12-31Cons.Profit loss
Total assets¥10.9bnat 2022-12-31Cons.Assets
Total assets¥10.4bnat 2022-03-31Cons.Assets
Total assets¥10.2bnat 2021-12-31Cons.Total assets (5-year summary)
Total liabilities¥4.2bnat 2022-12-31Cons.Liabilities
Total liabilities¥3.8bnat 2022-03-31Cons.Liabilities
Net assets / equity¥6.7bnat 2022-12-31Cons.Net assets
Net assets / equity¥6.6bnat 2022-03-31Cons.Net assets
Net assets / equity¥5.6bnat 2021-12-31Cons.Net assets (5-year summary)
Cash and deposits¥3.4bnat 2022-12-31Cons.Cash and deposits
Cash and deposits¥4.6bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥10.812022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥7.542022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥109.522021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥46.572021-04-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-10.552021-10-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥109.312021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥46.462021-04-01 → 2021-12-31Cons.Diluted earnings per share (5-year summary)
Equity ratio60.4%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio62.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio53.7%at 2021-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 31
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥4m
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-12-31¥2m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥6m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥157m
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥1.8bn
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥1.8bn
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥5m
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥132m
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥6.7bn
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥6.7bn
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥1m
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥179m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-12-31¥8.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-12-31¥8.5bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-12-31¥6m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-12-31¥310m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-12-31−¥9m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-12-31−¥9m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31−¥138m
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥3.9bn
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥3.9bn
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥9m
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥1.7bn
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥5.7bn
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥5.7bn
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥491,000
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥203m
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-12-31¥9.7bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-12-31¥9.6bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-12-31¥9m
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-12-31¥1.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 368
ItemContextValueUnit
Loss on retirement of noncurrent assets elPrior1YTDDuration－JPY
Loss on retirement of noncurrent assets elCurrentYTDDuration3575000JPY
Loss on reduction of noncurrent assets elPrior1YTDDuration288951000JPY
Loss on reduction of noncurrent assets elCurrentYTDDuration－JPY
Loss on valuation of investment securities elPrior1YTDDuration130790000JPY
Loss on valuation of investment securities elCurrentYTDDuration－JPY
Other elPrior1YTDDuration－JPY
Other elCurrentYTDDuration300000JPY
Extraordinary lossPrior1YTDDuration589116000JPY
Extraordinary lossCurrentYTDDuration51632000JPY
Income before income taxesPrior1YTDDuration1391697000JPY
Income before income taxesCurrentYTDDuration344292000JPY
Income taxes currentPrior1YTDDuration638764000JPY
Income taxes currentCurrentYTDDuration8318000JPY
Income taxes deferredPrior1YTDDuration-41941000JPY
Income taxes deferredCurrentYTDDuration164904000JPY
Income taxesPrior1YTDDuration596823000JPY
Income taxesCurrentYTDDuration173222000JPY
Profit lossPrior1YTDDuration794874000JPY
Profit lossCurrentYTDDuration171069000JPY
Profit loss attributable to non controlling interestsPrior1YTDDuration-7779000JPY
Profit loss attributable to non controlling interestsCurrentYTDDuration-10989000JPY
Profit loss attributable to owners of parentPrior1YTDDuration802653000JPY
Profit loss attributable to owners of parentCurrentYTDDuration182059000JPY
Profit lossPrior1YTDDuration794874000JPY
Profit lossCurrentYTDDuration171069000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration88630000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration-7054000JPY
Foreign currency translation adjustment net of tax ociPrior1YTDDuration9120000JPY
Foreign currency translation adjustment net of tax ociCurrentYTDDuration7413000JPY
Other comprehensive incomePrior1YTDDuration97751000JPY
Other comprehensive incomeCurrentYTDDuration358000JPY
Comprehensive incomePrior1YTDDuration892626000JPY
Comprehensive incomeCurrentYTDDuration171428000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration900404000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration182417000JPY
Comprehensive income attributable to non controlling interestsPrior1YTDDuration-7778000JPY
Comprehensive income attributable to non controlling interestsCurrentYTDDuration-10989000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember3922291000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember5722793000JPY
Revenues from external customersPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember9645084000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration9645084000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember9000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember491000JPY
Transactions with other segmentsPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember9491000JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember-9491000JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember3931291000JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E05317-000InvestmentsAndConsultingBusinessReportableSegmentsMember5723285000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass